REGN vs. ZTS: Regeneron Pharmaceuticals vs. Zoetis Stock Comparison

November 11, 2026

How do Regeneron Pharmaceuticals (REGN) and Zoetis (ZTS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Regeneron Pharmaceuticals (REGN) and Zoetis (ZTS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but REGN is classified in Biotechnology while ZTS is classified in Pharmaceuticals.

Company profile comparison for Regeneron Pharmaceuticals (REGN) and Zoetis (ZTS)
Profile Item	REGN	ZTS
Name	Regeneron Pharmaceuticals, Inc.	Zoetis Inc. Class A Common Stock
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Pharmaceuticals
GICS Sub-Industry	Biotechnology	Pharmaceuticals
Market Capitalization	93.55 billion USD	32.26 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	April 2, 1991	February 1, 2013
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

REGN

ZTS

GSPC

Regeneron Pharmaceuticals (REGN) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Regeneron Pharmaceuticals (REGN) and Zoetis (ZTS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Regeneron Pharmaceuticals (REGN) and Zoetis (ZTS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Regeneron Pharmaceuticals (REGN) and Zoetis (ZTS)
Metric	REGN	ZTS
Total Return (1Y)	40.87%	-30.10%
Total Return (3Y, Annualized)	5.15%	-20.42%
Total Return (5Y, Annualized)	8.58%	-16.87%

Risk Profile

Drawdown History

REGN

ZTS

GSPC

Regeneron Pharmaceuticals (REGN) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Regeneron Pharmaceuticals (REGN) and Zoetis (ZTS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Regeneron Pharmaceuticals (REGN) and Zoetis (ZTS)
Metric	REGN	ZTS
Volatility (1Y, Annualized)	34.08%	38.23%
Beta (5Y)	0.10	0.66
Max Drawdown (5Y)	-59.69%	-70.45%
Avg. Volume (3M)	772.95K	4.65M

Risk-Adjusted Performance

Risk-Return Positioning

REGN and ZTS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Regeneron Pharmaceuticals (REGN) and Zoetis (ZTS)
Metric	REGN	ZTS
Sharpe Ratio (1Y)	1.07	-0.90
Sortino Ratio (1Y)	1.70	-1.10

Profitability

ROE (TTM)

Both Regeneron Pharmaceuticals (REGN) at 14.95% and Zoetis (ZTS) at 57.63% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.95%

Max: 109.18%
REGN: 14.95%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

57.63%

Max: 109.18%
ZTS: 57.63%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Regeneron Pharmaceuticals (REGN) vs. Zoetis (ZTS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Regeneron Pharmaceuticals (REGN) at 28.51% and Zoetis (ZTS) at 26.41% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.51%

REGN: 28.51%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.41%

ZTS: 26.41%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Regeneron Pharmaceuticals (REGN) vs. Zoetis (ZTS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Regeneron Pharmaceuticals (REGN) at 40.46% and Zoetis (ZTS) at 38.19% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

40.46%

Max: 83.12%
REGN: 40.46%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.19%

Max: 83.12%
ZTS: 38.19%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Regeneron Pharmaceuticals (REGN) vs. Zoetis (ZTS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Regeneron Pharmaceuticals (REGN) and Zoetis (ZTS)
Metric	REGN	ZTS
ROE (TTM)	14.95%	57.63%
ROA (TTM)	7.59%	14.87%
Net Margin (TTM)	28.51%	26.41%
Operating Margin (TTM)	40.46%	38.19%
Gross Margin (TTM)	46.73%	71.65%

Growth

Revenue Growth

Both Regeneron Pharmaceuticals (REGN) at 0.99% and Zoetis (ZTS) at 2.28% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Regeneron Pharmaceuticals (REGN) vs. Zoetis (ZTS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Regeneron Pharmaceuticals (REGN) at 8.19% and Zoetis (ZTS) at 10.05% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Regeneron Pharmaceuticals (REGN) vs. Zoetis (ZTS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Regeneron Pharmaceuticals (REGN) and Zoetis (ZTS)
Metric	REGN	ZTS
Revenue Growth (YoY)	0.99%	2.28%
Revenue Growth (3Y CAGR)	5.62%	5.42%
EPS Growth (YoY)	8.19%	10.05%
EPS Growth (3Y CAGR)	2.77%	10.27%

Financial Strength

Current Ratio (MRQ)

Regeneron Pharmaceuticals (REGN) at 3.35 keeps current ratio within its industry’s typical mid-range, while Zoetis (ZTS) at 2.35 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ZTS.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.35

Max: 25.13
Q3: 12.13
Median: 5.52
REGN: 3.35
Q1: 2.47
Min: 0.10

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.35

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
ZTS: 2.35
Min: 0.10

Regeneron Pharmaceuticals (REGN) vs. Zoetis (ZTS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Regeneron Pharmaceuticals (REGN) at 0.08 is near its industry mid-range for debt-to-equity ratio, while Zoetis (ZTS) at 2.80 sits above its benchmark range, pointing to a heavier debt load relative to equity.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.08

Max: 1.42
Q3: 0.65
Median: 0.15
REGN: 0.08
Q1: 0.02
Min: 0.00

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.80

ZTS: 2.80
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Regeneron Pharmaceuticals (REGN) vs. Zoetis (ZTS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Regeneron Pharmaceuticals (REGN) and Zoetis (ZTS)
Metric	REGN	ZTS
Current Ratio (MRQ)	3.35	2.35
Debt / Equity (MRQ)	0.08	2.80
Net Debt / EBITDA	-1.17	1.92

Dividends

Dividend Yield (TTM)

Both Regeneron Pharmaceuticals (REGN) at 0.41% and Zoetis (ZTS) at 2.55% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.41%

REGN: 0.41%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.55%

ZTS: 2.55%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Regeneron Pharmaceuticals (REGN) vs. Zoetis (ZTS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Regeneron Pharmaceuticals (REGN) at 8.18% and Zoetis (ZTS) at 35.24% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.18%

REGN: 8.18%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.24%

ZTS: 35.24%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Regeneron Pharmaceuticals (REGN) vs. Zoetis (ZTS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Regeneron Pharmaceuticals (REGN) and Zoetis (ZTS)
Metric	REGN	ZTS
Dividend Yield (TTM)	0.41%	2.55%
Dividend Payout Ratio (TTM)	8.18%	35.24%

Valuation

P/E Ratio (TTM)

Both Regeneron Pharmaceuticals (REGN) at 19.99 and Zoetis (ZTS) at 13.50 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.99

Max: 85.34
Q3: 43.46
Median: 26.69
REGN: 19.99
Q1: 13.30
Min: 0.07

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.50

Max: 85.34
Q3: 43.46
Median: 26.69
ZTS: 13.50
Q1: 13.30
Min: 0.07

Regeneron Pharmaceuticals (REGN) vs. Zoetis (ZTS): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Regeneron Pharmaceuticals (REGN) at 5.54 and Zoetis (ZTS) at 3.40 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.54

Max: 58.18
Q3: 25.77
Median: 7.30
REGN: 5.54
Q1: 3.01
Min: 0.01

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.40

Max: 58.18
Q3: 25.77
Median: 7.30
ZTS: 3.40
Q1: 3.01
Min: 0.01

Regeneron Pharmaceuticals (REGN) vs. Zoetis (ZTS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Regeneron Pharmaceuticals (REGN) at 2.71 is valued about in line with its industry on P/B ratio, while Zoetis (ZTS) at 9.80 carries an above-peer premium to book — ZTS is pricier on assets.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.71

Max: 13.53
Q3: 6.54
Median: 3.25
REGN: 2.71
Q1: 1.69
Min: -5.59

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.80

Max: 13.53
ZTS: 9.80
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Regeneron Pharmaceuticals (REGN) vs. Zoetis (ZTS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Regeneron Pharmaceuticals (REGN) and Zoetis (ZTS)
Metric	REGN	ZTS
P/E Ratio (TTM)	19.99	13.50
P/S Ratio (TTM)	5.54	3.40
P/B Ratio (MRQ)	2.71	9.80
Free Cash Flow Yield (TTM)	2.76%	6.36%